ERBB2 and cancer: AUY922, an HSP90 inhibitor, demonstrates synergistic anti-cancer activity with lapatinib in HER2-positive cancers by destabilizing oncogenic client proteins and modulating stress responses, potentially including ferroptosis-related pathways (80).